{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T09:09:53Z","timestamp":1782551393161,"version":"3.54.5"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2,1]]},"DOI":"10.2146\/ajhp130203","type":"journal-article","created":{"date-parts":[[2014,1,15]],"date-time":"2014-01-15T18:52:41Z","timestamp":1389811961000},"page":"191-198","source":"Crossref","is-referenced-by-count":11,"title":["Perampanel: A new agent for adjunctive treatment of partial seizures"],"prefix":"10.1093","volume":"71","author":[{"given":"Michele A.","family":"Faulkner","sequence":"first","affiliation":[{"name":"Department of Neurology, School of Medicine, Creighton University, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2019041605214194100_b1-0710191","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/B978-0-444-52898-8.00006-9","article-title":"The epidemiology of the epilepsies","volume":"107","author":"Neligan","year":"2012","journal-title":"Handb Clin Neurol"},{"key":"2019041605214194100_b2-0710191","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra1004418","article-title":"Current concepts: drug-resistant epilepsy","volume":"365","author":"Kwan","year":"2011","journal-title":"N Engl J Med"},{"key":"2019041605214194100_b3-0710191","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/jnnp.2004.045690","article-title":"The natural history of epilepsy: an epidemiological view","volume":"75","author":"Kwan","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2019041605214194100_b4-0710191","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.epilep.2012.11.004","article-title":"Pharmacological treatment strategies: mechanisms of antiepileptic drugs","volume":"1","author":"Potschka","year":"2013","journal-title":"Epileptology"},{"key":"2019041605214194100_b5-0710191","first-page":"71","article-title":"Glutamate receptors","volume-title":"Mechanisms of action of antiepileptic drugs","author":"White","year":"2010","edition":"1st ed"},{"key":"2019041605214194100_b6-0710191","first-page":"263","article-title":"Perampanel study 207: long-term open-label evaluation in patients with epilepsy","volume":"126","author":"Rektor","year":"2012","journal-title":"Acta Neurol Scand"},{"key":"2019041605214194100_b7-0710191","first-page":"225","article-title":"The dawn of excitatory amino acid research in Japan. The pioneering work by Professor Takashi Hayashi","volume":"29","author":"Takagaki","year":"1996","journal-title":"Neurochem Int"},{"key":"2019041605214194100_b8-0710191","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/0140-6736(93)90754-5","article-title":"Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain","volume":"341","author":"During","year":"1993","journal-title":"Lancet"},{"key":"2019041605214194100_b9-0710191","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2165\/00002512-200118100-00001","article-title":"Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging","volume":"18","author":"Le","year":"2001","journal-title":"Drugs Aging"},{"key":"2019041605214194100_b10-0710191","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5698\/1535-7511-11.2.56","article-title":"Revisiting AMPA receptors as an antiepileptic drug target","volume":"11","author":"Rogawski","year":"2011","journal-title":"Epilepsy Curr"},{"key":"2019041605214194100_b11-0710191","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40263-012-0021-2","article-title":"Perampanel as adjunctive therapy in patients with partial onset seizures","volume":"26","author":"Plosker","year":"2012","journal-title":"CNS Drugs"},{"key":"2019041605214194100_b12-0710191","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.nurt.2006.11.010","article-title":"Molecular targets for antiepileptic drug development","volume":"4","author":"Meldrum","year":"2007","journal-title":"Neurotherapeutics"},{"key":"2019041605214194100_b13-0710191","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.conb.2005.05.004","article-title":"Glutamate receptor ion channels","volume":"15","author":"Mayer","year":"2005","journal-title":"Curr Opin Neurobiol"},{"key":"2019041605214194100_b14-0710191","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1126\/science.280.5369.1596","article-title":"The tetrameric structure of a glutamate receptor channel","volume":"280","author":"Rosenmund","year":"1998","journal-title":"Science"},{"key":"2019041605214194100_b15-0710191","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0079-6123(02)35046-5","article-title":"Implications for neuroprotective treatments","volume":"135","author":"Meldrum","year":"2002","journal-title":"Prog Brain Res"},{"key":"2019041605214194100_b16-0710191","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1023\/A:1025666207754","article-title":"AMPA receptor-mediated neurotoxicity: role of Ca2+ and desensitization","volume":"28","author":"Frandsen","year":"2003","journal-title":"Neurochem Res"},{"key":"2019041605214194100_b17-0710191","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrneurol.2012.222","article-title":"Perampanel\u2014new promise for refractory epilepsy?","volume":"8","author":"L\u00f6scher","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"2019041605214194100_b18-0710191","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2012.12.006","article-title":"Novel treatment options for epilepsy: focus on perampanel","volume":"70","author":"Franco","year":"2013","journal-title":"Pharmacol Res"},{"key":"2019041605214194100_b19-0710191","doi-asserted-by":"crossref","article-title":"Demographic factors and concomitant antiepileptic drugs have no effect on the pharmacodynamics of perampanel","author":"Hussein","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P06.127"},{"issue":"suppl 6","key":"2019041605214194100_b20-0710191","first-page":"248","article-title":"Population pharmacokinetics of perampanel, a selective, noncompetitive AMPA receptor antagonist, in patients with refractory partial-onset seizures participating in a randomized, double-blind, placebo-controlled phase III study","volume":"52","author":"Hussein","year":"2011","journal-title":"Epilepsia"},{"issue":"suppl 1","key":"2019041605214194100_b21-0710191","first-page":"1.254","article-title":"Population pharmacokinetics and pharmacodynamics of perampanel in patients with refractory partial seizures","volume":"11","author":"Fuseau","year":"2011","journal-title":"Epilepsy Curr"},{"issue":"suppl 11","key":"2019041605214194100_b22-0710191","first-page":"98","article-title":"Pharmacokinetics of perampanel, a highly selective AMPA-type glutamate receptor antagonist","volume":"50","author":"Templeton","year":"2009","journal-title":"Epilepsia"},{"issue":"suppl 1","key":"2019041605214194100_b23-0710191","first-page":"2.231","article-title":"Population pharmacokinetics and pharmacodynamics of perampanel: a pooled analysis from three phase III trials","volume":"12","author":"Laurenza","year":"2012","journal-title":"Epilepsy Curr"},{"key":"2019041605214194100_b24-0710191","volume-title":"Fycompa (perampanel) package insert","year":"2012"},{"key":"2019041605214194100_b25-0710191","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"key":"2019041605214194100_b26-0710191","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"key":"2019041605214194100_b27-0710191","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 306","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"key":"2019041605214194100_b28-0710191","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1528-1167.2012.03648.x","article-title":"Perampanel, a selective, noncompetitive \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307","volume":"54","author":"Krauss","year":"2013","journal-title":"Epilepsia"},{"issue":"suppl 5","key":"2019041605214194100_b29-0710191","first-page":"194","article-title":"Analysis of seizure frequency reduction by concomitant antiepileptic drug (AED) use with adjunctive perampanel: pooled phase III results","volume":"53","author":"Trinka","year":"2012","journal-title":"Epilepsia"},{"key":"2019041605214194100_b30-0710191","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0404.2011.01588.x","article-title":"Tolerability and safety of perampanel: two randomized dose-escalation studies","volume":"125","author":"Krauss","year":"2012","journal-title":"Acta Neurol Scand"},{"key":"2019041605214194100_b31-0710191","unstructured":"Gilbert\n              JA\n            \n          . Eisai files a writ of mandamus as a last resort to get DEA to schedule Fycompa. www.fdalawblog.net\/fda_law_blog_hyman_phelps\/2013\/08\/eisai-files-a-writ-of-mandamus-as-a-last-resort-to-get-dea-to-schedule-fycompa-.html (accessed 2013 Nov 1)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/71\/3\/191\/28451037\/ajhp0191.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T09:22:33Z","timestamp":1555406553000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/71\/3\/191\/5111121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,1]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,2,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp130203","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,2,1]]},"published":{"date-parts":[[2014,2,1]]}}}